Evaluation of

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Metastatic colorectal cancer (mCRC) management relies on accurate RAS mutation status.
• Tissue biopsy for RAS mutation analysis can be invasive and may not reflect tumor heterogeneity.
• Liquid biopsy offers a less invasive alternative for molecular profiling.

Purpose of the Study:

• To evaluate the diagnostic performance of BEAMing technology for detecting K-RAS and N-RAS mutations in plasma samples from mCRC patients.
• To compare the sensitivity and specificity of liquid biopsy with tissue-based RAS analysis.
• To explore the correlation between RAS mutation allele fraction and clinical parameters, and its potential for monitoring disease progression.

Main Methods:

• Plasma samples from mCRC patients were analyzed for K-RAS and N-RAS mutations using BEAMing technology.
• Results were compared with RAS mutation status determined from tissue biopsies.
• Mutant allele fraction (MAF) levels were analyzed in relation to tumor characteristics, metastasis, treatment, and disease progression.

Main Results:

• BEAMing demonstrated 89.5% sensitivity for KRAS mutations with fair specificity; agreement with tissue analysis was moderate.
• High sensitivity and good specificity were observed for NRAS mutations, with fair agreement with tissue analysis.
• Higher MAF levels were associated with G2 tumors, liver metastases, no surgery, mucinous adenocarcinoma, and lung metastases.
• A significant increase in MAF preceded radiological signs of disease progression, indicating molecular progression anticipates radiological progression.

Conclusions:

• Liquid biopsy with BEAMing technology is a viable tool for detecting RAS mutations in mCRC.
• This method can effectively monitor treatment response and anticipate disease progression earlier than radiological assessments.
• The findings support the use of liquid biopsy for improved patient management and timely therapeutic interventions in mCRC.